Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
Putluri N, Maity S, Kommagani R, Creighton CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T, Nardone A, Fu X, Shaw C, Sarkar TR, Schiff R, Lydon JP, O'Malley BW, Ambs S, Das GM, Michailidis G, Sreekumar A.
Putluri N, et al. Among authors: lydon jp.
Neoplasia. 2014 May;16(5):390-402. doi: 10.1016/j.neo.2014.05.007.
Neoplasia. 2014.
PMID: 25016594
Free PMC article.